Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.
Antimicrob Agents Chemother
; 66(6): e0227621, 2022 06 21.
Article
en En
| MEDLINE
| ID: mdl-35652307
ABSTRACT
Candida auris is an emerging multidrug-resistant human fungal pathogen often refractory to treatment by all classes of antifungal drugs. Amphotericin B (AmB) is a fungicidal drug that, despite its toxic side effects, remains a drug of choice for the treatment of drug-resistant fungal infections, including those caused by C. auris. However, the molecular mechanisms underlying AmB resistance are poorly understood. In this study, we present data that suggests membrane lipid alterations and chromatin modifications are critical processes that may contribute to or cause adaptive AmB resistance in clinical C. auris isolates. To determine the plausible cause of increased AmB resistance, we performed RNA-seq of AmB-resistant and sensitive C. auris isolates. Remarkably, AmB-resistant strains show a pronounced enrichment of genes involved in lipid and ergosterol biosynthesis, adhesion, drug transport as well as chromatin remodeling. The transcriptomics data confirm increased adhesion and reduced lipid membrane permeability of AmB-resistant strains compared to the sensitive isolates. The AmB-resistant strains also display hyper-resistance to cell wall perturbing agents, including Congo red, calcofluor white and caffeine. Additionally, we noticed an increased phosphorylation of Mkc1 cell integrity MAP kinase upon AmB treatment. Collectively, these data identify differences in the transcriptional landscapes of AmB-resistant versus AmB-sensitive isolates and provide a framework for the mechanistic understanding of AmB resistance in C. auris.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Candidiasis
/
Anfotericina B
Límite:
Humans
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos